Exagen Review Shows AVISE Lupus Identifies 25% More SLE Cases With 98% Specificity
XGN•Exagen’s systematic review of AVISE Lupus consolidated data from over 3,100 individuals across 14 centers, showing 98% specificity, AUC up to 0.90 and unique identification of 25% more SLE patients missed by standard serologies. The results strengthen its premium market position and support broader adoption and reimbursement.
1. Study Scope and Data Consolidation
The systematic review evaluated biomarker data for 3,132 individuals across 14 academic medical centers, covering studies from 2011 to 2025 and building on the original clinical validation of over 1,200 SLE patients.
2. Key Diagnostic Performance Metrics
AVISE Lupus demonstrated specificity above 98%, an AUC reaching 0.90 and uniquely identified 25% of SLE patients who would have been missed by conventional serologic tests such as anti-dsDNA, anti-Smith, C3 and C4.
3. Strategic and Commercial Implications
These robust real-world results reinforce Exagen’s premium market positioning, bolster its reimbursement strategy and are likely to accelerate adoption among rheumatologists, potentially driving future revenue growth.
